大和:削富智康(2038.HK)目標至1.05港元 維持“優於大市”評級
大和發表研究報告指,富智康集團(2038.HK)去年下半年業績表現強勁,去年下半年毛利率改善至2.6%,高於該行預期,儘管隨着疫情爆發,今年上半年富智康業務受到挑戰,但料今年下半年情況將會好轉,將其目標價由1.18港元下調至1.05港元,維持“優於大市”投資評級。
該行續指,今年上半年中國及印度因應疫情有不同程度地區封鎖,料今年上半年富智康毛利率下降至1.4%,以及錄得淨虧損4500萬美元,但隨著情況改善,料富智康於今年將會轉虧為盈,錄純利6300萬美元,結束從2017年起集團一直錄得虧損的情況。
該行表示,下調今年每股盈利預測25%,但上調明年每股盈利預測18%,亦認為現時富智康估值吸引。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.